BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37153541)

  • 1. Prognostic significances of PD-L1- and CTLA-4-positive T cells and positive correlations of immunosuppressive marker expression between cancer tissue and peripheral blood in patients with gastric cancer.
    Lee KH; Kim SJ; Woo JS; Lee SY; Jhun J; Moon J; Jung YJ; Cho ML; Song KY
    Front Immunol; 2023; 14():1138743. PubMed ID: 37153541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
    Pereira MA; de Castria TB; Ramos MFKP; Dias AR; Cardili L; de Moraes RDR; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
    J Surg Oncol; 2021 Dec; 124(7):1040-1050. PubMed ID: 34255356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.
    Kim JW; Nam KH; Ahn SH; Park DJ; Kim HH; Kim SH; Chang H; Lee JO; Kim YJ; Lee HS; Kim JH; Bang SM; Lee JS; Lee KW
    Gastric Cancer; 2016 Jan; 19(1):42-52. PubMed ID: 25424150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
    Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
    Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
    Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer.
    Lee SY; Jhun J; Woo JS; Lee KH; Hwang SH; Moon J; Park G; Choi SS; Kim SJ; Jung YJ; Song KY; Cho ML
    Gut Microbes; 2024; 16(1):2300846. PubMed ID: 38197259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
    Ma J; Li J; He N; Qian M; Lu Y; Wang X; Wu K
    J Transl Med; 2023 Feb; 21(1):73. PubMed ID: 36737759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
    Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M
    Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cohort study using IL-6/Stat3 activity and PD-1/PD-L1 expression to predict five-year survival for patients after gastric cancer resection.
    Li XN; Peng YH; Yue W; Tao L; Zhang WJ
    PLoS One; 2022; 17(12):e0277908. PubMed ID: 36454780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
    Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
    DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.
    Wei H; Wu F; Mao Y; Zhang Y; Leng G; Wang J; Zhang W; Wang T
    Jpn J Clin Oncol; 2022 Apr; 52(4):331-345. PubMed ID: 35106596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
    Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
    Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
    Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
    Guo J; Qu H; Shan T; Chen Y; Chen Y; Xia J
    Mol Cells; 2018 Jul; 41(7):653-664. PubMed ID: 29936792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
    Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
    J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
    Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
    Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.